CHEMICAL SCREENING AND OPTIMIZATION FACILITY - "SCALABLE QUANTITIES OFACTIVE PHARMACEUTICAL INGREDIENTS"

化学筛选和优化设施 - “活性药物成分的可扩展数量”

• 批准号: 10274475
• 负责人: LEYI GONG
• 金额: $ 20.14万
• 依托单位: SRI INTERNATIONAL
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-24 至 2021-09-23
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10274475
• 关键词: Award; Biochemical; Biological; Biological Assay; Characteristics; Chemicals; Contraceptive Agents; Contraceptive methods; Development; Female Contraceptive Agents; Formulation; Generations; Goals; Male Contraceptive Agents; Methods; Mission; Molecular; National Institute of Child Health and Human Development; Oogenesis; Outcome; Ovulation; Pharmaceutical Chemistry; Pharmacologic Substance; Pharmacology; Play; Process; Production; Recombinant Proteins; Research; Research Support; Role; Services; Sperm Maturation; Spermatogenesis; Testing; Woman; X-Ray Crystallography; assay development; chemical synthesis; computational chemistry; drug development; high throughput screening; in silico; melting; men; preclinical evaluation; recombinant peptide; screening

The Contraception Research Branch (CRB) within the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) supports research to develop compounds that can disrupt oogenesis, spermatogenesis, ovulation, sperm maturation and/or function affording safe and effective contraceptives for men and/or women. The Chemical Screening and Optimization Facility (CSOF) fulfills a unique role by identifying, optimizing, and conducting small scale production of molecular agents that achieve a contraceptive effect. The CSOF provides overall project management and the capabilities to support these objectives pursuant to development of new contraceptive methods: these include, but are not limited to, the generation of recombinant peptides and proteins, assay development, high throughput screening (HTS), x-ray crystallography, computational chemistry, medicinal chemistry, and pharmacology. Compounds identified and/or optimized by the CSOF will be prepared under non-Good Manufacturing Practices (non-GMP) for further preclinical evaluation. The CSOF plays a critical role in the drug development mission of the CRB.

尤尼斯·肯尼迪·施莱佛国家研究所避孕研究分支（CRB） 儿童健康和人类发展（NICHD）支持研究开发化合物， 卵子发生、精子发生、排卵、精子成熟和/或提供安全和 为男性和/或女性提供有效的避孕药具。 化学筛选与优化 设施（CSOF）通过识别、优化和进行小规模的 产生实现避孕效果的分子药剂。 CSOF提供全面的 项目 管理 和 的 能力 到 支持 这些 目标 根据 到 开发新的避孕方法：这些方法包括但不限于： 重组肽和蛋白质，检测开发，高通量筛选（HTS），x射线 晶体学、计算化学、药物化学和药理学。 化合物 由CSOF确定和/或优化的产品将在非良好生产条件下制备 用于进一步临床前评价的规范（非GMP）。CSOF在药物中起着关键作用 CRB的发展使命。